Brief: Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases
12/02/2026 14:03
Feb 12 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS RECEIVES U.S. NOTICE OF ALLOWANCE FOR NOVEL EXON-SKIPPING THERAPY TARGETING ALLERGIC DISEASES Source text: ID:nPn2KtBbJa Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology